5440672026-04-012026-06-305440672026-04-012026-06-30in-capmkt:OtherExpenses1Member5440672026-04-012026-06-30in-capmkt:OtherExpenses2Member5440672026-04-012026-06-30in-capmkt:OtherExpenses3Member5440672026-04-012026-06-30in-capmkt:OtherExpenses4Member5440672026-04-012026-06-30in-capmkt:OtherExpenses5Member5440672026-04-012026-06-30in-capmkt:OtherExpenses6Member5440672026-04-012026-06-30in-capmkt:OtherExpenses7Member5440672026-04-012026-06-30in-capmkt:OtherExpenses8Member5440672026-04-012026-06-30in-capmkt:OtherExpenses9Member5440672026-04-012026-06-30in-capmkt:OtherExpenses10Member5440672026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15440672026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares544067INNOVACAPNOTLISTEDINE0DUT01020INNOVA CAPTAB LIMITEDMain BoardEquity2026-04-012027-03-312026-08-112026-08-06INRMillionsQuarterlyFirst quarterSingle segmentDrugs and Pharmaceutical products2026-08-1116:07:002026-08-1116:47:00Not applicablefalsefalseAs the Company has not defaulted in repayment of loan. Hence disclosure is not applicable.2026-04-012026-06-30UnauditedStandalone4004760000270200004031780000280366000065000000-7530000303450000403300009684000029969000036014400004303400000430340000691300004061000010974000003206000000000320600000-1260000319340000572250000105.65.6005.65.61 The above unaudited standalone financial results of Innova Captab Limited the Company have been prepared in accordance with recognition and measurement principles laid down under Indian Accounting Standard 34 Interim Financial Reporting Ind AS 34 prescribed under Section 133 of the Companies Act 2013 the act read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations 2015 Listing Regulation as amended The results for the quarter ended 30 June 2026 are available on the Company's website ie www.innovacaptab.com under investor relations section and on the stock exchange websites ie www.nseindia.com and www.bseindia.com <br /> 2 The above unaudited standalone financial results have been reviewed and recommended by Audit Committee at its meeting held on 11 August 2026 The Board of Directors at their meeting held on 11 August 2026 have approved the above results and taken them on record The statutory auditors of the Company have expressed an unmodified review conclusion on the unaudited standalone financial results for the quarter ended 30 June 2026 <br /> 3 The Company has only one reportable segment ie Drugs and pharmaceutical products as per Ind AS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per SEBI LODR regulations or Listing Regulations are not applicable to the Company <br /> 4 The figures of the last quarter ended 31 March 2026 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year Also the figures upto the end of the third quarter had only been reviewed and not subject to audit <br /> 5 Subsequent to the approval of the standalone financial statements for the year ended 31 March 2026 by the Board of directors on 07 May 2026 certain inadvertent errors were identified and the Company is in the process of making the necessary corrections to such standalone financial statements prior to the adoption of such standalone financial statements at ensuing annual general meeting These matters do not have any material impact on the standalone financial results for the quarter ended 30 June 2026 or on the comparative information presented thereinPower and fuel61240000Freight charges57450000Packing charges45750000Stores and spares consumed29240000Repairs and maintenance28620000Rates, fees and taxes14600000House keeping expense11440000Lab consumables10800000Travelling and conveyance8900000Other expenses316500001 The Company has only one reportable segment ie Drugs and pharmaceutical products as per Ind AS 108 Operating Segments specified under section 133 of the Companies Act 2013Remeasurement of defined benefit obligation-1690000Income tax relating to items that will not be reclassified to profit or loss430000-126000000-1260000